The discovery and development of rivaroxaban

Authors

  • Frank Misselwitz,

    1. Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development, Bayer HealthCare AG, Wuppertal, Germany.
    Search for more papers by this author
  • Scott D. Berkowitz,

    1. Thrombosis and Hemostasis Group, Cardiovascular and Coagulation Therapeutic Area, Global Clinical Development, Bayer HealthCare Pharmaceuticals, Montville, New Jersey.
    Search for more papers by this author
  • Elisabeth Perzborn

    1. Bayer HealthCare Pharmaceuticals, Cardiovascular Pharmacology, Global Therapeutic Research, Bayer HealthCare AG, Wuppertal, Germany
    Search for more papers by this author

Address for correspondence: Scott D. Berkowitz, Thrombosis and Hemostasis Group, Cardiovascular and Coagulation Therapeutic Area, Global Clinical Development, Bayer HealthCare Pharmaceuticals, P.O. Box 1000, Mailstop M2/2-7, Montville, New Jersey 07045-1000. scott.berkowitz@bayer.com

Abstract

Thromboembolic conditions present a considerable challenge to healthcare services because they are associated with substantial morbidity and mortality. The mainstays of prevention and treatment are anticoagulants and antiplatelet agents. Established anticoagulants have drawbacks that make their use difficult to manage and sustain. This has stimulated the search for new oral anticoagulants that are more convenient and yet still effective. This paper describes the development and future potential of rivaroxaban (Xarelto™; Bayer Schering Pharma AG, Berlin, Germany)—the first oral, direct Factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.

Ancillary